Wikipedia:WikiProject Chemicals/Chembox validation/VerifiedDataSandbox and Lymecycline: Difference between pages
Appearance
(Difference between pages)
Content deleted Content added
Saving copy of the {{drugbox}} taken from revid 456799040 of page Lymecycline for the Chem/Drugbox validation project (updated: 'DrugBank'). |
IB autocalculates MW |
||
Line 1: | Line 1: | ||
{{Short description|Chemical compound}} |
|||
{{ambox | text = This page contains a copy of the infobox ({{tl|drugbox}}) taken from revid [{{fullurl:Lymecycline|oldid=456799040}} 456799040] of page [[Lymecycline]] with values updated to verified values.}} |
|||
{{Drugbox |
{{Drugbox |
||
| Verifiedfields = changed |
| Verifiedfields = changed |
||
| Watchedfields = changed |
| Watchedfields = changed |
||
| verifiedrevid = |
| verifiedrevid = 462094956 |
||
| IUPAC_name = (2''S'')-6-<nowiki>[[[</nowiki>(''Z'')-[(4''S'',4a''S'',5a''S'',6''S'',12a''S'') -4-( |
| IUPAC_name = (2''S'')-6-<nowiki>[[[</nowiki>(''Z'')-[(4''S'',4a''S'',5a''S'',6''S'',12a''S'') -4-(Dimethylamino)-6,10,11,12a-tetrahydroxy-6-methyl-1,3,12-trioxo-4,4a,5,5a-tetrahydrotetracen-2-ylidene]-hydroxymethyl]amino]methylamino]-2-aminohexanoic acid |
||
| image = Lymecycline |
| image = Lymecycline.svg |
||
| width = |
| width = 300 |
||
<!--Clinical data--> |
<!--Clinical data--> |
||
| tradename = |
| tradename = Tetralysal |
||
| Drugs.com = {{drugs.com|international|lymecycline}} |
| Drugs.com = {{drugs.com|international|lymecycline}} |
||
| pregnancy_category = |
| pregnancy_category = |
||
| legal_status = |
| legal_status = |
||
| legal_AU = Schedule 4 |
|||
| routes_of_administration = |
| routes_of_administration = [[Oral administration|By mouth]] |
||
<!--Pharmacokinetic data--> |
<!--Pharmacokinetic data--> |
||
| bioavailability = 100% (oral) |
| bioavailability = 100% (oral) |
||
| metabolism = |
| metabolism = |
||
| elimination_half-life = 10 |
| elimination_half-life = 10 hours |
||
| excretion = [[ |
| excretion = [[Kidney]] |
||
<!--Identifiers--> |
<!--Identifiers--> |
||
Line 26: | Line 27: | ||
| ATC_prefix = J01 |
| ATC_prefix = J01 |
||
| ATC_suffix = AA04 |
| ATC_suffix = AA04 |
||
| PubChem = |
| PubChem = 54707177 |
||
| DrugBank_Ref = {{drugbankcite|correct|drugbank}} |
| DrugBank_Ref = {{drugbankcite|correct|drugbank}} |
||
| DrugBank = DB00256 |
| DrugBank = DB00256 |
||
| ChemSpiderID_Ref = {{chemspidercite| |
| ChemSpiderID_Ref = {{chemspidercite|changed|chemspider}} |
||
| ChemSpiderID = |
| ChemSpiderID = 20121315 |
||
| UNII_Ref = {{fdacite| |
| UNII_Ref = {{fdacite|correct|FDA}} |
||
| UNII = 7D6EM3S13P |
| UNII = 7D6EM3S13P |
||
| KEGG_Ref = {{keggcite|correct|kegg}} |
| KEGG_Ref = {{keggcite|correct|kegg}} |
||
Line 38: | Line 39: | ||
<!--Chemical data--> |
<!--Chemical data--> |
||
| C=29 | H=38 | N=4 | O=10 |
| C=29 | H=38 | N=4 | O=10 |
||
| smiles = C[C@@]1([C@H]2C[C@H]3[C@@H](C(=C(C(=O)[C@]3(C(=C2C(=O)C4=C1C=CC=C4O)O)O)C(=O)NCNCCCC[C@@H](C(=O)O)N)O)N(C)C)O |
|||
| molecular_weight = 602.63 |
|||
⚫ | |||
| smiles = OC(=O)[C@H](CCCCN)NCNC(=O)\C1=C(/O)[C@@H](N(C)C)[C@@H]2CC4C(=C(\O)[C@]2(O)C1=O)\C(=O)c3c(cccc3O)[C@@]4(C)O |
|||
⚫ | |||
⚫ | |||
⚫ | |||
⚫ | |||
⚫ | |||
⚫ | |||
⚫ | |||
}} |
}} |
||
'''Lymecycline''' is a [[tetracycline antibiotics|tetracycline]] [[broad-spectrum antibiotic]]. It is approximately 5,000 times more [[soluble]] than [[tetracycline]] base and is unique amongst tetracyclines in that it is [[Absorption (chemistry)|absorbed]] by an [[active transport]] process across the intestinal wall, making use of the same fast and efficient mechanism by which [[carbohydrate]]s are absorbed.<ref>[[New Zealand]] [http://www.medsafe.govt.nz/profs/Datasheet/t/Tetralysalcap.htm Datasheet] {{webarchive|url=https://web.archive.org/web/20060303205705/http://www.medsafe.govt.nz/profs/datasheet/t/Tetralysalcap.htm |date=2006-03-03 }} August 2003</ref> |
|||
The greater absorption of lymecycline allows for lower dosages to be used; the standard dose of 408 mg is equivalent to 300 mg tetracycline base and, in its action, to 500 mg tetracycline hydrochloride. Lymecycline, unlike tetracycline hydrochloride, is soluble at all [[physiological]] [[pH]] values.{{cn|date=March 2023}} |
|||
==History== |
|||
Lymecycline was introduced by [[Farmitalia]] in 1963.{{cn|date=March 2023}} |
|||
==Indications== |
|||
Lymecycline, like other tetracyclines, is used to treat a range of infections. |
|||
=== Acne === |
|||
Its better absorption profile makes it preferable to tetracycline for moderately severe [[Acne vulgaris|acne]] and typically prescribed for 8 weeks at a time, but alternatives should be sought if no improvement occurs by 3 months.<ref>[[British National Formulary]] ''45'' March 2003</ref> |
|||
[[File:Tetralysal tablets with packaging in background.jpg|thumb|250px|Lymecycline capsules]] |
|||
== Side effects == |
|||
Lymecycline's side effects can include [[rash]], [[headache]], [[Diarrhea|diarrhoea]], [[nausea]], [[vomiting]], [[dermatitis]], inflammation of the liver, [[Hypersensitive response|hypersensitive reactions]], and [[Vision disorder|visual disturbances]]. When taken for a long period of time, it can cause [[reflux oesophagitis]].<ref>{{cite web| vauthors = Wang P |title=Side effects of Tetralysal|url=http://www.steadyhealth.com/about/side_effects_of_tetralysal.html|access-date=23 March 2011}}</ref> Recently, the family of tetracycline antibiotics has been associated with thyroid dysfunction in youth.<ref>{{cite journal | vauthors = Pollock AJ, Seibert T, Allen DB | title = Severe and Persistent Thyroid Dysfunction Associated with Tetracycline-Antibiotic Treatment in Youth | journal = The Journal of Pediatrics | volume = 173 | pages = 232–4 | date = June 2016 | pmid = 27059913 | pmc = 4884496 | doi = 10.1016/j.jpeds.2016.03.034 }}</ref> |
|||
== See also == |
|||
* [[Timeline of antibiotics]] |
|||
== References == |
|||
{{Reflist}} |
|||
{{TetracyclineAntiBiotics}} |
|||
[[Category:Alpha-Amino acids]] |
|||
[[Category:Amino acid derivatives]] |
|||
[[Category:Anti-acne preparations]] |
|||
[[Category:Tetracycline antibiotics]] |